STERIS announced a $600 million investment to build a 600,000-square-foot Formulated Chemistries Center of Excellence in North Carolina, targeting infection prevention chemistries. The project will relocate existing production from Missouri and Minnesota and is slated to begin operations in 2–3 years, with about 335 new jobs. The plan signals a durable, long-term capacity expansion and potential efficiency gains across the U.S. chemistries network.
Steris has forecasted its fiscal 2027 profit to surpass Wall Street expectations, driven by strong demand for its sterilization services. Despite narrowly missing Q4 adjusted profit estimates, the outlook reflects investor confidence in the company's core offerings, likely resulting in positive market reactions.
Steris reported Q4 2025 revenue of $1.48B, beating estimates. Net income increased to $270.3M from $257.4M year-over-year. Earnings per share rose to $2.74 compared to $2.60 last year.
